Stryker Co. (SYK) Stake Raised by JLB & Associates Inc.
JLB & Associates Inc. increased its stake in Stryker Co. (NYSE:SYK) by 0.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 35,817 shares of the medical technology company’s stock after buying an additional 110 shares during the quarter. JLB & Associates Inc.’s holdings in Stryker were worth $5,614,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Moody Lynn & Lieberson LLC lifted its holdings in Stryker by 50.8% during the 3rd quarter. Moody Lynn & Lieberson LLC now owns 75,135 shares of the medical technology company’s stock valued at $13,350,000 after purchasing an additional 25,316 shares during the last quarter. First Citizens Bank & Trust Co. lifted its holdings in shares of Stryker by 318.9% during the third quarter. First Citizens Bank & Trust Co. now owns 6,840 shares of the medical technology company’s stock worth $1,216,000 after buying an additional 5,207 shares in the last quarter. Marshall & Sullivan Inc. WA lifted its holdings in shares of Stryker by 1.6% during the third quarter. Marshall & Sullivan Inc. WA now owns 28,389 shares of the medical technology company’s stock worth $5,044,000 after buying an additional 449 shares in the last quarter. Banco Santander S.A. acquired a new stake in shares of Stryker during the third quarter worth $3,169,000. Finally, Hall Laurie J Trustee lifted its holdings in shares of Stryker by 2.7% during the third quarter. Hall Laurie J Trustee now owns 39,182 shares of the medical technology company’s stock worth $6,962,000 after buying an additional 1,025 shares in the last quarter. 73.30% of the stock is owned by institutional investors.
SYK has been the subject of a number of research reports. Zacks Investment Research raised Stryker from a “hold” rating to a “buy” rating and set a $195.00 target price for the company in a report on Wednesday, December 5th. Cowen set a $195.00 target price on Stryker and gave the stock a “buy” rating in a report on Friday, November 9th. Deutsche Bank began coverage on Stryker in a report on Wednesday, January 2nd. They set a “buy” rating and a $179.00 target price for the company. Oppenheimer set a $170.00 price target on Stryker and gave the stock a “hold” rating in a research report on Friday, October 26th. Finally, Needham & Company LLC restated a “hold” rating on shares of Stryker in a research report on Friday, November 9th. Eight investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. Stryker presently has a consensus rating of “Buy” and a consensus target price of $181.68.
Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, October 25th. The medical technology company reported $1.69 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.68 by $0.01. The company had revenue of $3.24 billion for the quarter, compared to analysts’ expectations of $3.26 billion. Stryker had a return on equity of 28.00% and a net margin of 9.31%. As a group, equities analysts forecast that Stryker Co. will post 7.28 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, January 31st. Stockholders of record on Monday, December 31st will be issued a dividend of $0.52 per share. This is a boost from Stryker’s previous quarterly dividend of $0.47. This represents a $2.08 annualized dividend and a dividend yield of 1.31%. The ex-dividend date is Friday, December 28th. Stryker’s payout ratio is 32.05%.
In other news, insider Timothy J. Scannell sold 9,332 shares of the business’s stock in a transaction dated Tuesday, December 18th. The stock was sold at an average price of $161.60, for a total transaction of $1,508,051.20. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP M Kathryn Fink sold 415 shares of the business’s stock in a transaction dated Monday, November 5th. The stock was sold at an average price of $166.56, for a total value of $69,122.40. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 12,108 shares of company stock worth $1,981,471. Company insiders own 7.30% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was originally posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this report on another domain, it was illegally stolen and republished in violation of U.S. and international trademark & copyright legislation. The original version of this report can be accessed at https://theolympiareport.com/2019/01/11/stryker-co-syk-stake-raised-by-jlb-associates-inc.html.
Stryker Company Profile
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Featured Article: What is the Rule of 72?
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.